Khalighfard Solmaz, Khori Vahid, Esmati Ebrahim, Ahmadi Farahnazsadat, Amiriani Taghi, Poorkhani Amirhoushang, Sadani Somayeh, Khodayari Saeed, Khodayari Hamid, Kalhori Mohammad Reza, Keshavarz Pedram, Alizadeh Ali Mohammad
Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Research Center on Developing Advanced Technologies, Tehran, Iran.
Med Oncol. 2023 Jan 6;40(2):74. doi: 10.1007/s12032-022-01935-1.
Filgrastim, a recombinant type of granulocyte-colony stimulating factor (G-CSF), has a high potential to manage chemotherapy-induced leukopenia. It can increase stromal cell-derived factor 1 (SDF-1) which may stimulate C-X-C chemokine receptor type 4 (CXCR4) to migrate bone marrow-derived stem/progenitor cells to the bloodstream. Here, we aimed to investigate in vitro and in vivo effects of filgrastim on cell migration, invasion, and metastasis. A lentivirus vector of the anti-CXCR4 receptor was first used for the CXCR4 knockout. Effects of filgrastim on cell proliferation and migration were then investigated on 4T1 cells by Transwell migration and wound healing assay. At last, the effects of filgrastim on cell metastasis and the possible involved mechanisms have been investigated in a metastatic murine breast tumor. The knockout of the CXCR4 receptor could lead to a decrease in cell proliferation, migration, and invasion of the 4T1 cells. Filgrastim could directly target SDF-1 and upregulate the expression of the CXCR4 receptor. The knockout of the CXCR4 receptor reduced cell metastasis in an animal model of breast cancer. CXCR4 receptor stimulation by the filgrastim-affected pathways is a conserved evolutionary response that could increase cancer cell proliferation and consequent cell metastasis. Our results suggest that the activation of the CXCR4 receptor is a conserved evolutionary response that can increase cell proliferation, migration, and consequent metastasis. It seems that filgrastim may increase the chance of cancer cell metastasis in people continuously receiving it to increase the number of neutrophils. Filgrastim induces the SDF-1/CXCR4 axis on tumor cell growth. SDF-1 and its receptor CXCR4 are vital targets for filgrastim. The CXCR4 can stimulate the PI3K/AKT, NF-κB, and JAK/STAT signaling pathways. The SDF-1/CXCR4 pathway promotes cell chemotaxis and proliferation via MAPKs signaling. It also enhances cell survival, proliferation, and angiogenesis, increasing tumor cell metastasis. The STAT3-mediated inflammation is essential for tumorigenesis processes, and Akt, Wnt, STAT3, and CXCR4 signaling pathways are all correlated. CXCR4 = C-X-C chemokine receptor type 4, SDF-1 = stromal-derived-factor-1, MAPK = mitogen activated protein kinase; NF-κB = nuclear factor-κB, PI3K = phosphoinositide 3-kinase, JAK = Janus kinase, STAT = signal transducer and activator of transcription, PLC = phospholipase C, PKC = Protein kinase C, GRK = G protein-coupled receptor kinase.
非格司亭是一种重组型粒细胞集落刺激因子(G-CSF),在治疗化疗引起的白细胞减少方面具有很高的潜力。它可以增加基质细胞衍生因子1(SDF-1),后者可能刺激C-X-C趋化因子受体4型(CXCR4),促使骨髓来源的干/祖细胞迁移至血流中。在此,我们旨在研究非格司亭在体外和体内对细胞迁移、侵袭和转移的影响。首先使用抗CXCR4受体的慢病毒载体进行CXCR4基因敲除。然后通过Transwell迁移实验和伤口愈合实验研究非格司亭对4T1细胞增殖和迁移的影响。最后,在转移性小鼠乳腺肿瘤中研究了非格司亭对细胞转移的影响及可能涉及的机制。CXCR4受体的敲除可导致4T1细胞的增殖、迁移和侵袭能力下降。非格司亭可直接作用于SDF-1并上调CXCR4受体的表达。在乳腺癌动物模型中,CXCR4受体的敲除可减少细胞转移。非格司亭影响的信号通路对CXCR4受体的刺激是一种保守的进化反应,可增加癌细胞增殖及随后的细胞转移。我们的结果表明,CXCR4受体的激活是一种保守的进化反应,可增加细胞增殖、迁移及随后的转移。似乎非格司亭可能会增加持续接受其治疗以增加中性粒细胞数量的人群中癌细胞转移的几率。非格司亭诱导SDF-1/CXCR4轴参与肿瘤细胞生长。SDF-1及其受体CXCR4是非格司亭的重要作用靶点。CXCR4可刺激PI3K/AKT、NF-κB和JAK/STAT信号通路。SDF-1/CXCR4通路通过MAPKs信号促进细胞趋化性和增殖。它还可增强细胞存活、增殖和血管生成,增加肿瘤细胞转移。STAT3介导的炎症对肿瘤发生过程至关重要,且Akt、Wnt、STAT3和CXCR4信号通路均相互关联。CXCR4 = C-X-C趋化因子受体4型,SDF-1 = 基质衍生因子-1,MAPK = 丝裂原活化蛋白激酶;NF-κB = 核因子-κB,PI3K = 磷脂酰肌醇3-激酶,JAK = Janus激酶,STAT = 信号转导及转录激活蛋白,PLC = 磷脂酶C,PKC = 蛋白激酶C,GRK = G蛋白偶联受体激酶